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Interactions between mycoplasmas and leukocytes are both specific and non-specific.
Phagocytosis is generally resisted until the mycoplasma is opsonized by specific antibody.
Lymphocytes react with mycoplasmas in a variety ofways; both stimulation and inhibition can
occur as a result ofantigenic (specific) or mitogenic (non-specific) properties ofthe organisms.
A variety of mitogenic substances are generated by mycoplasmas of different origin and
their effect on B cells, macrophages, and T cells also varies. Apparently, non-specific mito-
genic stimulation is a significant component ofthe immune response to mycoplasmas. Regula-
tion of these organism/host interactions is not random, however. Receptors for mycoplasma
attachment or interaction are under genetic control, suggesting that certain hosts are more
susceptible to both specific and non-specific immune stimulation.
As extracellular parasites, mycoplasmas are exposed to the host immune system
during all phases of the infectious process. Thus, the interaction between
mycoplasmas and immunological cells is relatively easy to study. Several stages of
interaction occur as infection with a mycoplasma proceeds [1]. Mycoplasmas, first,
must attach to a surface epithelium in order to function as agents ofdisease. This is
a dynamic process, in situ, with multiplication and reattachment occurring con-
tinuously in order to maintain colonization. Turnover ofinfected cells allows for in-
teraction of cellular and humoral components of the host defenses at several levels:
e.g., mechanical clearance, anti-attachment antibody, growth-inhibiting and
complement-mediated lysis, opsonization, phagocytosis, antigen processing, and
generation of specific immune products.
Before specific immunity develops, phagocytes are generally unable to approach
and engulf mycoplasmas. This phenomenon has been observed by several groups of
investigators and would appear to be an adaptive mechanism which permits survival
of the organisms as they initiate infection [2,3].
Interaction between lymphocytes and mycoplasmas has been studied extensively
and a variety ofreactions has been observed [4]. The most obvious is the generation
of serum and secretory antibodies in response to localized infection. Such antibody
production is a sure sign of B-lymphocyte stimulation, although the exact pathway
by which mycoplasma antigens are processed to produce antibodies is unknown.
Presumably lung macrophages and regional lymph nodes are involved in the pro-
cess.
In addition to specific antibody synthesis, certain mycoplasmas contain mitogens
which activate B lymphocytes non-specifically: so-called polyclonal activation [5].
Non-specific T-lymphocyte activation by mycoplasmas is less common. Biberfeld
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showed M. pneumoniae activates mouse and human B lymphocytes but not T cells
[5,6]. M. fermentans is reported to activate both B and T lymphocytes from humans
[7]. Naot has shown M. pulmonis stimulates rat B and T lymphocytes [8] but M.
neurolyticum is mitogeneic only for B cells [9]. Further evidence of T-lymphocyte
activation is presented by detection of interferon production, as discussed in this ses-
sion by Dr. Arai and in one of the poster sessions by Dr. Cole. Dr. Arai's observa-
tions add an additional mechanism for non-specific activation of lymphocytes by
providing evidence that H202 can stimulate interferon production.
Interactions of mycoplasma mitogens and lymphocytes apparently are not ran-
dom. Barry Cole has reviewed evidence in this symposium that M. arthritidis
mitogenic activity depends upon an la bearing accessory cell population,
presumably macrophages. As discussed by Barry Cole, these observations suggest
that certain strains of animals, and perhaps certain humans as well, are more suscep-
tible to both specific and non-specific immune stimulation by mycoplasmas.
Perhaps the reason that some subjects suffer pneumonia and even distant, ex-
trapulmonary effects of infection, while others experience only mild symptons, is
related to genetic control. Further research in this area should be rewarding for
students of infectious disease.
Dr. Wise's efforts to develop monoclonal antibodies to M. hyorhinis surface an-
tigens will help to promote research on the nature of lymphocyte/mycoplasma in-
teraction. Much of the present research in infectious diseases has been spawned by
the new technology for producing monoclonal antibodies. As characterization of
immune interactions between host and infecting organism moves ahead, much more
precision can be expected in defining these reactions. This will certainly be welcomed
and may help to clear up some of the confusion we presently have concerning
specificity of the immune response as defined by conventional diagnostic methods.
Dr. Naot's studies of the interactions of two mycoplasma mitogens with elements
of the immune system illustrate further variability between species of both organism
and host. Clearly, a variety of mitogenic substances are generated by mycoplasmas
of different origin and their effect on B cells, macrophages, and T cells also varies. If
one extends these and the experiments of others, including Biberfeld and Cole, it is
apparent that non-specific, mitogenic stimulation is a significant component of the
immune response to mycoplasmas.
Dr. Naot's studies of in vivo effects of M. pulmonis membranes link mitogenicity
to pathogenicity since pulmonary lesions, indistinguishable from those seen in in-
fected rats, are induced by instillation of non-viable organisms in the lung [10]. Not
only can local immune stimulation occur in vivo as illustrated in the rat/pulmonis
model, systemic activation of B lymphocytes can also occur as illustrated by
Biberfeld's presentation in this symposium of non-specific titer rises of virus an-
tibodies in patients with M. pneumoniae pneumonia.
In discussing interactions of mycoplasmas with phagocytes, Dr. Howard has
pointed out that both inhibitory and stimulatory responses are seen. In the absence
of specific antibody, mycoplasmas seem to evade phagocytosis. The appearance of
antibody arms the macrophage for phagocytosis and, in the presence of antibody
and complement, PMN phagocytosis is optimized.
In attempting to understand how all of these interactions occur, I can only con-
clude that the immune response to mycoplasmas is complex, certainly more so than
we once thought. Nevertheless, some of the peculiar features of mycoplasma infec-
tions may relate to the phenomena described in this symposium. Thus, the pro-
longed colonization of mucous membranes characteristic of mycoplasma infections
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may be promoted by resistance to phagocytosis and inhibition of a specific immune
response. Certainly the well-accepted concept that the pathologic lesions are in large
part due to host reactivity is compatible with the mitogenic properties of these
organisms. Probably much of the local immuno-inflammatory response, which has
been interpreted as "reactive immunity" in the past is, in fact, non-specific in nature
[11]. Finally, the many strange antibodies found in sera ofM. pneumoniae-infected
patients may be due to polyclonal activation of B lymphocytes. Thus, in interpreting
immunologic reactions to mycoplasmas, one must consider that not only specific,
but non-specific, stimulation is occurring and also that some degree ofimmune sup-
pression may be a concurrent part of the overall immune response.
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